Company Overview
Bioceres Crop Solutions Corp. functions within the agricultural inputs sector, specifically focusing on the development and commercialization of crop productivity solutions across seed and integrated products, crop protection, and crop nutrition segments. The company operates in the Basic Materials industry, where it leverages its operations to provide essential traits, germplasms, and seeds to support agricultural output. In terms of scale, Bioceres maintains a market capitalization of $24.95M with an annual revenue of $318.16M and an employee base of 751 individuals. These financial figures indicate that while the company generates substantial top-line revenue relative to its market cap, suggesting potential undervaluation or significant reinvestment in operations, the employee count of 751 reflects a mid-sized organizational structure capable of supporting diverse commercialization efforts. The disparity between the revenue of $318.16M and the market cap of $24.95M highlights a company where current market pricing may not yet fully reflect its revenue generation capabilities or where recent market dynamics have adjusted valuation significantly. This positioning places Bioceres in a category where market cap metrics must be interpreted with caution alongside revenue data to understand its true operational footprint.
Financial Health
The company reported a revenue of $318.16M over the trailing twelve months, yet recorded a net income of $-56,374,676 and an EBITDA of $11.81M. The substantial gap between the positive revenue of $318.16M and the negative net income of $-56,374,676 reveals a cost structure where operating expenses, including interest costs or significant depreciation, are consuming a large portion of gross profits before reaching the bottom line. Free cash flow stands at $-423,547, indicating that the company is currently generating more cash outflows than inflows from operations and investing activities, which limits immediate financial flexibility for capital allocation without external financing. Profitability is further detailed by a gross margin of 39.4%, an operating margin of 8.9%, and a negative profit margin of -17.7%, showing that while the company retains nearly 40% of sales as gross profit, high overhead costs reduce operating margins, and losses ultimately drive the bottom line into negative territory. Liquidity and leverage are critical considerations, with cash on hand of $16.61M standing in stark contrast to total debt of $258.45M, while the debt-to-equity ratio is an elevated 89.64, signaling a highly leveraged balance sheet rather than a conservative one. Short-term liquidity appears constrained as the current ratio is 0.94, suggesting that current assets may not fully cover current liabilities without refinancing or asset liquidation. Return metrics further illustrate operational challenges, with a return on equity of -18.9% and a return on assets of -0.4%, revealing that management has not yet achieved positive returns on shareholder capital or the asset base during this period.
Valuation Assessment
Valuation metrics present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of 0.61, implying that the market expects a rapid normalization of earnings or a significant turnaround in profitability to justify future price targets. The price-to-book ratio is 0.09, indicating that the stock trades at a fraction of its book value, which often suggests the market has priced in significant risks or expects future earnings to be insufficient to support current asset valuations. Alternative valuation measures include a price-to-sales ratio of 0.08 and an EV/EBITDA of 25.83, suggesting that while revenue multiples are extremely low, the enterprise value relative to earnings before interest, taxes, depreciation, and amortization remains high, reflecting the cost of the substantial debt load or high interest expenses impacting the denominator. Price volatility is evident given the 52-week high of $5.17 and a low of $0.35; assuming a current trading price near the recent averages implied by these extremes, the stock is trading at a significant discount relative to its 52-week high, highlighting the recent downward pressure on the security. Risk profile is quantified by a beta of 0.46, which indicates that the stock price is less volatile than the broader market, moving with less intensity than the general index.
Growth & Income
Growth dynamics show a revenue growth of -16.4% year-over-year, while earnings growth is N/A due to the negative net income position, implying that the company is currently contracting in terms of top-line sales and has not yet returned to profitability to calculate meaningful earnings growth rates. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that instead of distributing cash to shareholders, the company is retaining all earnings to fund operations or debt reduction, although current earnings are negative. This reinvestment strategy is typical for companies in the seed and agricultural inputs space that prioritize R&D and market expansion over shareholder distributions when profitability is not yet established. The overall growth and income profile is characterized by a contraction in revenue, a lack of dividend income, and a reliance on future operational improvements to restore both profitability and cash generation capabilities.